Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03728972 · ClinicalTrials.gov registry record · Phase 2
Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type
A Phase 2 study of NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis) and NK/T-Cell Lymphoma of Nasopharynx (Diagnosis), sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 10
- Study locations
NCT03728972: Active Phase 2 study of NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis) and NK/T-Cell Lymphoma of Nasopharynx (Diagnosis), sponsored by Memorial Sloan Kettering Cancer Center.
NCT03728972 is a Phase 2 study of NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis) and NK/T-Cell Lymphoma of Nasopharynx (Diagnosis) that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 19 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). The trial reports 10 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03728972, a Phase 2 study of NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis) and NK/T-Cell Lymphoma of Nasopharynx (Diagnosis), is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to test how well pembrolizumab shrinks Early-Stage NK/T-cell Lymphoma (ENKTL) in participants who have not yet received chemotherapy.
Conditions Studied
Interventions
- DRUG Pembrolizumab
Study Locations (10)
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Hackensack Meridian Health - Hackensack
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
New York
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
California
- Stanford University - Stanford
Texas
- Md Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-11-09 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
What the registry record for NCT03728972 still lists
NCT03728972 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis) appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT03728972 lists 10 locations in 4 states (New Jersey, New York, California).
Frequently Asked Questions
What is clinical trial NCT03728972 about?
NCT03728972 is a clinical study titled "Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type". The purpose of this study is to test how well pembrolizumab shrinks Early-Stage NK/T-cell Lymphoma (ENKTL) in participants who have not yet received chemotherapy.
What is the current status of trial NCT03728972?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2018-11-09. Estimated completion is 2026-11.
What conditions does trial NCT03728972 study?
This clinical trial studies the following conditions: NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis), NK/T-Cell Lymphoma of Nasopharynx (Diagnosis).
What interventions are being tested in trial NCT03728972?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT03728972?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03728972 being conducted?
This trial has 10 study locations across California, New Jersey, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03728972's enrollment target sits among peer trials
19 1894th of 2000 higher than 103 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI